(CercleFinance.com) – Sanofi announces positive data from the pivotal phase III XTEND-Kids study which evaluated ALTUVIIIO, at a weekly prophylactic dose, in patients under 12 years of age with hemophilia A severe that has already been treated.
These breaking data were presented during a clinical trial news session at the annual meeting of the International Society of Thrombosis and Hemostasis (ISTH) in Montreal.
They confirm that a weekly dose of 50 IU/kg of ALTUVIIIO provides highly effective protection against bleeding, in both adults and children, and that this regimen is suitable for all clinical scenarios.